摘è¦
èƒŒæ™¯ï¼šä»¥å¾€çš„ç ”ç©¶è¡¨æ˜Žï¼Œè‹”è—“æŠ‘ç´ -1,一ç§å¼ºåŠ›çš„PKC调制器和α分泌活化剂,通过长期的(> 10周),腹腔给è¯ï¼ˆi.p.)å¯æ”¹å–„阿尔茨海默æ°ç—…(AD)的认知水平。我们在APPSWE,PSEN1dE985Dbo(APP / PS1)的ADå°é¼ 模型ä¸æ¯”较å¦ä¹ 和空间记忆能力 ï¼Œç ”ç©¶äº†åœ¨æ¤æ¨¡åž‹ä¸æ€¥æ€§è…¹è…”内和å£æœç»™äºˆè‹”è—“æŠ‘ç´ -1对认知缺陷的逆转情况。相比于野生型(WT )å°é¼ ,APP / PS1å°é¼ 表现出显著的å¦ä¹ 能力差,寻找在Morris水迷宫测验ä¸å‘现漂浮æ¿ä½ç½®çš„时间延长。 在进行水迷宫测试å‰è‹”è—“æŠ‘ç´ 1ç»™è¯2å‘¨æ£€æµ‹ç»“æžœï¼šæ€¥æ€§è…¹è…”ç»™äºˆè‹”è—“æŠ‘ç´ 1没有改善延迟,但å£æœç»™äºˆè‹”è—“æŠ‘ç´ 1显著æ高了å°é¼ 记忆能力(通过测é‡ç‰å¾…逃脱时间是å¦å‡å°‘)。在测试的第3å¤©ï¼Œè‹”è—“æŠ‘ç´ -1å£æœç»™è¯çš„æ•ˆæžœæœ€æ˜Žæ˜¾ã€‚è¿™äº›ç ”ç©¶ç»“æžœè¡¨æ˜Žï¼š1)在å¦ä¹ 和记忆模型ä¸ï¼Œè‹”è—“æŠ‘ç´ -1å£æœæœ‰æ•ˆã€‚2)这ç§æ•ˆæžœçš„产生时间å¯ä»¥åœ¨å°‘于2周。3)腹腔注射给è¯æ— 效。我们的结论是å£æœè‹”è—“æŠ‘ç´ 1是未æ¥ä¸´åºŠä¸Šç”¨äºŽæ²»ç–—人类AD的,一ç§æ–°çš„ã€æœ‰æ•ˆã€é•¿æ•ˆçš„记忆增强剂。
关键è¯: β-æ·€ç²‰æ ·è›‹ç™½ï¼Œå»¶ç¼“è¡°è€ï¼Œbryoids,水迷宫,记忆,海马。
Current Alzheimer Research
Title:Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 1
Author(s): L.M. Schrott, K. Jackson, P. Yi, F. Dietz, G.S. Johnson, T.F. Basting, G. Purdum, T. Tyler, J.D. Rios, T.P. Castor and J.S. Alex
Affiliation:
关键è¯: β-æ·€ç²‰æ ·è›‹ç™½ï¼Œå»¶ç¼“è¡°è€ï¼Œbryoids,水迷宫,记忆,海马。
摘è¦: Background: Previous studies showed that Bryostatin-1, a potent PKC modulator and alphasecretase activator, can improve cognition in models of Alzheimer’s disease (AD) with chronic (>10 weeks), intraperitoneal (i.p.) administration of the drug. We compared learning and spatial memory in the APPswe, PSEN1dE985Dbo (APP/PS1) mouse model of AD and studied the ability of acute intraperitoneal and oral Bryostatin-1 to reverse cognitive deficits in this model. Compared to wild-type (WT) mice, APP/PS1 mice showed significant delays in learning the location of a submerged platform in the Morris water maze. Bryostatin-1 was administered over a 2-week course prior to and during water maze testing. Results: Acute i.p. Bryostatin-1 administration did not improve latency to escape but oral Bryostatin-1 significantly improved memory (measured by a reduction in latency to escape). This benefit of oral Bryostatin-1 administration was most apparent during the first 3 days of testing. These findings show that: 1) Bryostatin-1 is orally active in models of learning and memory, 2) this effect can be produced in less than 2 weeks and 3) this effect is not seen with i.p. administration. We conclude that oral Bryostatin-1 represents a novel, potent and long-acting memory enhancer with future clinical applications in the treatment of human AD.
Export Options
About this article
Cite this article as:
Schrott L.M., Jackson K., Yi P., Dietz F., Johnson G.S., Basting T.F., Purdum G., Tyler T., Rios J.D., Castor T.P. and Alex J.S., Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218141904
DOI https://dx.doi.org/10.2174/1567205012666141218141904 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynorphin Convertases and their Functions in CNS
Current Pharmaceutical Design Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents
Current Medicinal Chemistry Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Environmentally Friendly Suzuki Aryl-Aryl Cross-Coupling Reaction
Current Organic Chemistry HIV Genetic Diversity: Biological and Public Health Consequences
Current HIV Research BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Current Alzheimer Research Discovering and Developing New Medicines for Malaria Control and Elimination
Infectious Disorders - Drug Targets EDITORIAL [Hot Topic: The Seven Biggest Risks Posed By DSM-5]
Current Psychiatry Reviews Dopamine D<sub>3</sub> Agonists in the Treatment of Parkinson's Disease
Current Topics in Medicinal Chemistry Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity
Current Alzheimer Research Acknowledgements to Reviewers:
Current Alzheimer Research GABA and Neuroactive Steroid Interactions in Glia: New Roles for Old Players?
Current Neuropharmacology Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets Nonfatal Suicidal Overdose of Olanzapine in an Adolescent
Current Drug Safety Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Biological Function of G-Quadruplex Nucleic Acids and Potential Application in Medicinal Chemistry)
Current Topics in Medicinal Chemistry